Ziopharm Oncology (ZIOP) 5.03 -0.04

ZIOPHARM Oncology, Inc.
(ZIOP) 5.03 -0.04

Last Trade:	5.02	Day Range:	4.94 - 5.10
Trade Time:	08:05PM	52wk Range:	3.55 - 7.16
Prev. Close:	5.06	Market Cap:	399.2M
Open:	5.00	Div Yield:	0
Volume:	276868	PE:
EPS:	-0.69

The Latest On ZIOP

UPDATE: JP Morgan Initiates Overweight on ZIOPHARM Oncology; Standard Bearing Asset 5/18/12 11:10am

ZIOPHARM Oncology Appoints Jason A. Amello as Executive Vice President and Chief Financial Officer 5/8/12 6:36am

Ziopharm Says Picasso 3 Trial Approaches 90% Completion 4/2/12 8:58am

UPDATE: Jefferies Reduces PT to $6 on ZIOPHARM Oncology 3/2/12 12:07pm

Collins Stewart: Palifosfamide P2 OS Data Bodes Well for P3 2/13/12 11:13am

ZIOPHARM Oncology Reports Positive Preliminary Palifosfamide Overall Survival Data From Randomized Phase 2 Study in Soft Tissue Sarcoma 2/13/12 7:45am

A Peek Into The Market Before The Trading Starts 2/6/12 8:24am

ZIOPHARM Announces FDA Acceptance of IND for Oral Palifosfamide 2/6/12 7:41am

ZIOPHARM Oncology Announces Recommendation by Independent Data Monitoring Committee to Continue Phase 3 Study of Palifosfamide in Metastatic Soft Tissue Sarcoma 1/30/12 7:41am

ZIOPHARM Oncology Prices Public Offering of Common Stock at $5.20 per Share 1/20/12 10:28am

ZIOPHARM Oncology Announces Proposed Public Offering of Common Stock; No Amount Given 1/19/12 5:07pm

From Earlier: ZIOPHARM Oncology Files Complaint Against Former Employees 12/23/11 8:11am

UPDATE: JP Morgan Initiates Overweight on ZIOPHARM Oncology; Standard Bearing Asset 5/18/12

ZIOPHARM Oncology Appoints Jason A. Amello as Executive Vice President and Chief Financial Officer 5/8/12

Ziopharm Says Picasso 3 Trial Approaches 90% Completion 4/2/12

UPDATE: Jefferies Reduces PT to $6 on ZIOPHARM Oncology 3/2/12

Collins Stewart: Palifosfamide P2 OS Data Bodes Well for P3 2/13/12

ZIOPHARM Oncology Reports Positive Preliminary Palifosfamide Overall Survival Data From Randomized Phase 2 Study in Soft Tissue Sarcoma 2/13/12

A Peek Into The Market Before The Trading Starts 2/6/12

ZIOPHARM Announces FDA Acceptance of IND for Oral Palifosfamide 2/6/12

ZIOPHARM Oncology Announces Recommendation by Independent Data Monitoring Committee to Continue Phase 3 Study of Palifosfamide in Metastatic Soft Tissue Sarcoma 1/30/12

ZIOPHARM Oncology Prices Public Offering of Common Stock at $5.20 per Share 1/20/12

ZIOPHARM Oncology Announces Proposed Public Offering of Common Stock; No Amount Given 1/19/12

From Earlier: ZIOPHARM Oncology Files Complaint Against Former Employees 12/23/11

Monday's NASDAQ Top Percentage Gainers: BroadSoft, Globalstar, ZIOPHARM, Novatel Wireless 8/9/11

Small Cap Stock on the Move (ZIOP) triple top break out new high above $6.50 4/6/11

A Peek Into The Market Before The Trading Starts 1/20/11

Calls Purchased As ZIOPHARM Oncology Pops (ZIOP) 12/21/10

Calls Purchased on ZIOPHARM Oncology (ZIOP) 10/5/10

ZIOP Initiated With Outperform 2/18/10

UPDATE: JP Morgan Initiates Overweight on ZIOPHARM Oncology; Standard Bearing Asset 5/18/12

UPDATE: Jefferies Reduces PT to $6 on ZIOPHARM Oncology 3/2/12

Collins Stewart: Palifosfamide P2 OS Data Bodes Well for P3 2/13/12

Global Hunter Initiates ZIOPHARM Oncology at Buy, $9 PT 12/15/11

Edison Investment Provides Color on Ziopharm Oncology 6/29/11

Jefferies Initiates ZIOPHARM At Buy, $8 PT 2/9/11

A Peek Into The Market Before The Trading Starts 1/20/11

ZIOP Initiated With Outperform 2/18/10

Trade ZIOP
NOW!

Partner Headlines

22 Biopharma Stocks With Breakout Potential in 2012 5/22/12

Biotech Stock Mailbag: Ampio, Cel-Sci and Ziopharm 4/5/12

4 Smart Money Stock Picks That Are Deeply Undervalued (AEL, OGXI, OZM, ZIOP) 3/19/12

5 Stocks Insiders Are Loading Up On 1/26/12

Insiders Trading ZIOP, DEI, PCYC, XRAY 1/24/12

The Biotech Stock 13F Review: What Hedge Funds Were Buying and Selling 11/16/11

Biotech Stock Mailbag: Somaxon, Transcept 10/7/11

5 Stocks With Huge Insider Buying 8/11/11

Insiders Trading FO, AEA, ZIOP, QLIK 8/10/11

Small Biotechs Are an Rx for March Madness 3/9/11

BIO CEO Conference Live Blog: Day 2 2/15/11

Press Releases

ZIOPHARM Oncology to Present at the Jefferies 2012 Global Healthcare Conference 5/30/12 GlobeNewswire

ZIOPHARM Oncology to Present at the 11th Annual JMP Securities Research Conference 5/9/12 GlobeNewswire

ZIOPHARM Oncology Appoints Jason A. Amello as Executive Vice President and Chief Financial Officer 5/8/12 GlobeNewswire

ZIOPHARM Reports First Quarter Financial Results 5/3/12 GlobeNewswire

ZIOPHARM Oncology to Present at the Deutsche Bank Securities 37th Annual Health Care Conference 5/2/12 GlobeNewswire

ZIOPHARM Oncology to Present at the 19th Annual Future Leaders in the Biotech Industry Conference 4/16/12 GlobeNewswire

ZIOPHARM Oncology Presents Compelling Data Showing Palifosfamide Activity in Breast Cancer Models at AACR Meeting 4/3/12 GlobeNewswire

ZIOPHARM Oncology Presents Preclinical Data at AACR Meeting Demonstrating Significant Anti-Tumor Activity With Two Immunotherapies Expressed in Vivo by a Regulated Gene System 4/2/12 GlobeNewswire

ZIOPHARM Oncology Provides Update on PICASSO 3 Trial 4/2/12 GlobeNewswire

ZIOPHARM Oncology Announces Preclinical Data on Palifosfamide and IL-12 Gene Delivery to be Presented at the American Association for Cancer Research Annual Meeting 2012 3/27/12 GlobeNewswire

ZIOPHARM Reports Fourth Quarter and Full Year 2011 Financial Results 2/29/12 GlobeNewswire

ZIOPHARM Oncology to Present at Upcoming Investor Conferences 2/21/12 GlobeNewswire

Get the latest ZIOP stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for ZIOPHARM Oncology, Inc. stock price.

ZIOPHARM Oncology, Inc. by YCharts

Ziopharm Oncology (ZIOP) 5.03 -0.04

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On ZIOP

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social